Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.

被引：4
|
作者：
Murphy, Janet E.
Ly, Leilana
Wo, Jennifer Yon-Li
Ryan, David P.
Clark, Jeffrey W.
Yeap, Beow Y.
Drapek, Lorraine C.
Blaszkowsky, Lawrence Scott
Parikh, Aparna Raj
Nipp, Ryan David
Kwak, Eunice Lee
Allen, Jill N.
Corcoran, Ryan Bruce
Faris, Jason Edward
Zhu, Andrew X.
Goyal, Lipika
DeLaney, Thomas F.
Ferrone, Cristina
Castillo, Carlos Fernandez-del
Weekes, Colin D.
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[4] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02115 USA
[5] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.392
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
392
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis
    Barenboim, Alex
    Lahat, Guy
    Geva, Ravit
    Nachmany, Ido
    Nakache, Richard
    Goykhman, Yaacov
    Brazowski, Eli
    Rosen, Galia
    Isakov, Ofer
    Wolf, Ido
    Klausner, Joseph M.
    Lubezky, Nir
    EJSO, 2018, 44 (10): : 1619 - 1623
  • [2] Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX
    Choi, Jin Ho
    Kim, Min Kyu
    Lee, Sang Hyub
    Park, Jin Woo
    Park, Namyoung
    Cho, In Rae
    Ryu, Ji Kon
    Kim, Yong-Tae
    Jang, Jin-Young
    Kwon, Wooil
    Kim, Hongbeom
    Paik, Woo Hyun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] OPTIMAL ADJUVANT THERAPY IN PATIENTS WITH BORDERLINE RESECTABLE AND LOCALLY ADVANCED PANCREATIC CANCER WHO HAD RECEIVED NEOADJUVANT FOLFIRINOX
    Choi, Jin Ho
    Kim, Min Kyu
    Lee, Sang Hyub
    Park, Namyoung
    Kim, Jung
    Cho, In Rae
    Ryu, Ji Kon
    Kim, Yong-Tae
    Paik, Woo Hyun
    GASTROENTEROLOGY, 2022, 162 (07) : S741 - S741
  • [4] Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas
    Blazer, Marlo
    Wu, Christina
    Goldberg, Richard M.
    Phillips, Gary
    Schmidt, Carl
    Muscarella, Peter
    Wuthrick, Evan
    Williams, Terrence M.
    Reardon, Joshua
    Ellison, E. Christopher
    Bloomston, Mark
    Bekaii-Saab, Tanios
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (04) : 1153 - 1159
  • [5] Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas
    Marlo Blazer
    Christina Wu
    Richard M. Goldberg
    Gary Phillips
    Carl Schmidt
    Peter Muscarella
    Evan Wuthrick
    Terrence M. Williams
    Joshua Reardon
    E. Christopher Ellison
    Mark Bloomston
    Tanios Bekaii-Saab
    Annals of Surgical Oncology, 2015, 22 : 1153 - 1159
  • [6] Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
    Ferrone, Cristina R.
    Marchegiani, Giovanni
    Hong, Theodore S.
    Ryan, David P.
    Deshpande, Vikram
    McDonnell, Erin I.
    Sabbatino, Francesco
    Santos, Daniela Dias
    Allen, Jill N.
    Blaszkowsky, Lawrence S.
    Clark, Jeffrey W.
    Faris, Jason E.
    Goyal, Lipika
    Kwak, Eunice L.
    Murphy, Janet E.
    Ting, David T.
    Wo, Jennifer Y.
    Zhu, Andrew X.
    Warshaw, Andrew L.
    Lillemoe, Keith D.
    Fernandez-del Castillo, Carlos
    ANNALS OF SURGERY, 2015, 261 (01) : 12 - 17
  • [7] PROGNOSTIC FACTORS FOR PATIENTS WITH BORDERLINE RESECTABLE OR LOCALLY ADVANCED PANCREATIC CANCER RECEIVING NEOADJUVANT FOLFIRINOX
    Choi, Young Hoon
    Lee, Sang Hyub
    You, Min Su
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    GASTROENTEROLOGY, 2019, 156 (06) : S321 - S322
  • [8] Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
    Choi, Jin G.
    Nipp, Ryan D.
    Tramontano, Angela
    Ali, Ayman
    Zhan, Tiannan
    Pandharipande, Pari
    Dowling, Emily C.
    Ferrone, Cristina R.
    Hong, Theodore S.
    Schrag, Deborah
    Fernandez-Del Castillo, Carlos
    Ryan, David P.
    Kong, Chung Yin
    Hur, Chin
    ONCOLOGIST, 2019, 24 (07): : 945 - 954
  • [9] Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
    Choi, Young Hoon
    Lee, Sang Hyub
    You, Min Su
    Shin, Bang Sup
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Kwon, Wooil
    Jang, Jin-Young
    Kim, Sun-Whe
    GUT AND LIVER, 2021, 15 (02) : 315 - 323
  • [10] Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma
    Temraz, Sally
    Nassar, Farah
    Hammoud, Miza Salim
    Mukherji, Deborah
    O'Reilly, Eileen M.
    Dbouk, Haifa
    Farhat, Fadi
    Charafeddine, Maya
    Faraj, Walid
    Khalifeh, Mohammad J.
    Abou-Alfa, Ghassan K.
    Shamseddine, Ali
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 735 - 742
12345